Lung-MAP 对晚期鳞状细胞肺癌的第二代测序分析(SWOG S1400)
S1400 是肺癌主方案中针对经治的 IV 期或复发鳞状细胞肺癌患者的前瞻性临床试验,用 FoundationOne 平台对 313 个癌症相关基因进行测序,共报告 2014 至 2019 年入组的 1672 例患者数据,发现 NFE2L2、KEAP1 与 PARP4 以及 CDKN2A 与 RB1 两组互斥改变,NFE2L2 与 KEAP1 改变合并与较差生存相关。
要点
- 1672 例经治晚期鳞状细胞肺癌患者接受 FoundationOne 313 基因 NGS 检测。
- 发现两组互斥改变:NFE2L2、KEAP1、PARP4;以及 CDKN2A、RB1(FDR<15%)。
- NFE2L2 与 KEAP1 改变合并与较差生存相关;PARP4 存在三个频发突变。
核心结论
- S1400 NGS 数据集是迄今临床试验中最大的肺鳞状细胞癌测序数据集,为生物标志物发现提供丰富资源。
- PARP4 与 NFE2L2 或 KEAP1 改变的互斥性提示 PARP4 可能在影响氧化应激反应和治疗耐药的关键通路中具有尚未阐明的作用。
研究设计与样本
- 肺癌主方案西南肿瘤协作组 S1400 入组既往接受过治疗的 IV 期或复发鳞状细胞癌患者,评估 NGS 生物标志物以分配治疗子研究。
- 肿瘤采用 Foundation Medicine 的 FoundationOne 研究平台进行 NGS,测序 313 个癌症相关基因的外显子和/或内含子。
- 进行了互斥基因集分析和 Selected Events Linked by Evolutionary Conditions across Human Tumors 分析以识别互斥和共现基因改变。
- 与从癌症基因组图谱下载的 495 例肺鳞状细胞癌数据进行比较;采用 Cox 比例风险模型评估遗传变异与生存的关联。
主要发现
- 报告了 2014 年至 2019 年间入组 S1400 的 1672 例患者的 NGS 数据。
- 互斥基因集分析识别出两组非重叠的互斥改变,错误发现率低于 15%:NFE2L2、KEAP1 和 PARP4;以及 CDKN2A 和 RB1。
- PARP4 显示三个频发突变提示功能意义:3116T>C(I1039T)、3176A>G(Q1059R)和 3509C>T(T1170I)。
- NFE2L2 和 KEAP1 改变合并与较差生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Squamous cell cancer (SqCC) is a lung cancer subtype with few targeted therapy options. Molecular characterization, that is, by next-generation sequencing (NGS), is needed to identify potential targets. Lung Cancer Master Protocol Southwest Oncology Group S1400 enrolled patients with previously treated stage IV or recurrent SqCC to assess NGS biomarkers for therapeutic sub-studies. METHODS: Tumors underwent NGS using Foundation Medicine's FoundationOne research platform, which sequenced the exons and/or introns of 313 cancer-related genes. Mutually exclusive gene set analysis and Selected Events Linked by Evolutionary Conditions across Human Tumors were performed to identify mutually exclusive and co-occurring gene alterations. Comparisons were performed with data on 495 lung SqCC downloaded from The Cancer Genome Atlas. Cox proportional hazards models were used to assess associations between genetic variants and survival. RESULTS: NGS data are reported for 1672 patients enrolled on S1400 between 2014 and 2019. Mutually exclusive gene set analysis identified two non-overlapping sets of mutually exclusive alterations with a false discovery rate of less than 15%: NFE2L2, KEAP1, and PARP4; and CDKN2A and RB1. PARP4, a relatively uncharacterized gene, showed three frequent mutations suggesting functional significance: 3116T>C (I1039T), 3176A>G (Q1059R), and 3509C>T (T1170I). When taken together, NFE2L2 and KEAP1 alterations were associated with poorer survival. CONCLUSIONS: As the largest dataset to date of lung SqCC profiled on a clinical trial, the S1400 NGS dataset establishes a rich resource for biomarker discovery. Mutual exclusivity of PARP4 and NFE2L2 or KEAP1 alterations suggests that PARP4 may have an uncharacterized role in a key pathway known to impact oxidative stress response and treatment resistance.
引用
- Kozono D, Hua X, Wu MC, et al. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). J Thorac Oncol. 2024. PMID: 39111731. doi:10.1016/j.jtho.2024.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。